Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (685)	10/6/2004 4:15:33 PM
From: Icebrg	Read Replies (1) \| Respond to of 1022

Biolex Announces the Further Expansion if Its Collaboration With Centocor Wednesday October 6, 1:43 pm ET PITTSBORO, N.C., Oct. 6 /PRNewswire/ -- Biolex, Inc., a privately held protein therapeutics company, announced today an expanded collaboration with Centocor, Inc. a wholly owned subsidiary of Johnson & Johnson, to include two additional proteins. These additions bring to six the number of Centocor antibodies being expressed using Biolex' proprietary LEX System(TM) in this ongoing collaboration. "The expansion of our collaboration with Centocor further demonstrates our technical progress and the results that have been achieved so far with the LEX System," said Jan Turek, President and CEO of Biolex. "We are appreciative of Centocor's ongoing confidence and commitment to working with the LEX System(TM) and hope that our relationship will continue to grow in the future." Biolex will carry out a commercial line creation project using its proprietary LEX System(TM) for each of these two additional Centocor proteins. At Centocor's option, Biolex may scale-up and manufacture these proteins following the commercial line creation phase. Financial terms of the collaboration have not been disclosed. The LEX System(TM) couples natural characteristics of the small green aquatic plant, Lemna, with advanced genetic engineering and protein recovery methods to create a transformational development and production technology with advantages over all other existing cell culture and next generation transgenic expression systems. The LEX System(TM) has been demonstrated to significantly enable hard-to-make proteins (such as peptides and cytokines) and monoclonal antibodies. About Biolex: Biolex, Inc. is a private, venture capital-backed biopharmaceutical company. Biolex is developing recombinant human therapeutic proteins that, until now, have been impossible or very expensive to develop in existing expression systems. Biolex' proprietary LEX System(TM) has demonstrated speed, regulatory and economic benefits with hard-to-make proteins and monoclonal antibodies. Biolex has a pipeline of proprietary products in development, and is partnering with pharmaceutical and biotechnology companies seeking the protein development and production benefits the LEX System(TM) offers. Biolex has entered into corporate partnerships with Bayer HealthCare LLC, Centocor, Inc., Debiopharm S.A., and a major pharmaceutical company. The Company's headquarters, research laboratories and clinical manufacturing facilities are based in Pittsboro, North Carolina. Visit the Company's web site at biolex.com .